Individuals with chronic migraine (CM) frequently use acute headache medications, including triptans, ergot derivatives, opioids, and simple and combination analgesics, which can result in medication overuse (MO) [1, 2] and lead to greater disability and further reduced quality of life [1–5]. Preventive migraine therapy is recommended in patients with failure or overuse of acute medication, frequent attacks (≥4 headache days per month), headaches that interfere with daily routines despite acute treatment, or adverse events associated with acute treatments [3, 6]. Despite the potential benefits, preventive therapy is often underutilized [7, 8, 9], and persistence with treatment is often poor due to lack of efficacy or intolerable side effects [10–12]. New preventive therapies may improve patient lives with superior treatment efficacy and tolerability compared with previously available migraine preventive therapies [12, 13].